Buy or sell guide
Should I Buy LLY Stock Right Now?
A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for Eli Lilly and Company.
Updated 2026-06-22
Wall Street currently rates LLY buy with a 12-month price target of $1271 (+15.8% upside). The sections below cover the bull case, key risks, and latest earnings context for LLY.
Wall Street
Buy45 analystsConsensus target
$1271 target (+15.8%)Current price $1098.13Analyst sentiment
No recent analyst posts capturedWaiting for fresh postsEarnings context
EPS beat 22.7%Reported Thu Apr 30Wall Street verdict
Should I Buy LLY Stock? Here's What Analysts Think
45 analysts currently cover LLY. Below is their consensus rating, price target range, and implied upside.
According to 45 analysts, Eli Lilly and Company (LLY) is rated Buy with a consensus 12-month price target of $1271 — representing 16% upside from today's price of $1098. The bull case target is $1400, the bear case is $1119.
LLYBuy
From 45 analyst ratings- Current price
- $1098.13
- Consensus Target
- $1271 (+15.8% upside)
- Forward P/E
- 30.0x
- Coverage
- 45 analyst ratings
High target$1400
Low target$1119
At $1098.13, the consensus setup implies +15.8% versus the 12-month target.
- 33 of 45 analysts lean Buy or Strong Buy, while 9 stay on Hold and 3 lean bearish.
- LLY trades at roughly 30.0x forward earnings, so the bull case still depends on growth staying strong.
- Analysts span a wide range from $1119 to $1400, so conviction matters as much as the consensus target.
Below, compare that institutional answer with the live analyst commentary on X for LLY right now.
Analyst ratings update weekly. Get LLY's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
2 of 2 analysts raised targetsJefferies $1350B of A Securities $1251
Jun 2026Live commentary on X
What Analysts Are Saying About Eli Lilly and Company Right Now
Real posts from high-reach stock analysts mentioning LLY, shown exactly as written. Sorted by engagement — most discussed first.
No recent posts captured
No high-reach analysts have posted about LLY in the last 7 days. Check back after the next earnings release or market-moving event.
Should you buy LLY?
Is LLY a Buy, Hold, or Sell Right Now?
A structured look at the bull case, the risks, and the most recent earnings execution for LLY before you decide whether to buy, hold, or sell.
Current setup
LLY beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
Bull Case
What keeps the long thesis intact
- Strong Revenue GrowthEli Lilly reported a 56% year-over-year revenue increase to $19.8 billion in Q1 2026, with EPS up 170% to $8.26.
- GLP-1 Market LeadershipMounjaro and Zepbound are projected to generate over $50 billion in revenue in 2026, with Foundayo expected to earn $1.6 billion.
- Robust Pipeline and R&DEli Lilly's $50 billion investment in manufacturing and a deep pipeline, including retatrutide, positions it for sustained leadership.
- Improving Profit MarginsNet profit margin increased to 31.7%, up from 23.5% a year prior, with expectations to reach around 40% in the coming years.
- Valuation DiscountCurrent share price of $934.60 is below the DCF fair value of $1,427.87, suggesting a 16.5% margin of safety.
Wall Street rates LLY buy, giving the bull case institutional backing from 45 analysts.
Watch Out For
What can break the setup quickly
- High Valuation ConcernsThe stock's P/E ratio of 40.5x is significantly higher than the industry average of 16.1x, leaving little room for error.
- Increasing CompetitionThe GLP-1 market faces threats from competitors like Novo Nordisk, with oral Wegovy potentially offering superior weight loss benefits.
- Pricing and Regulatory RisksRisks for drugs like Kisunla include bottlenecks in patient diagnosis and potential cannibalization of existing products.
- Execution RisksWhile margins have improved, they are still below the expected 40% target, posing risks for future drug launches.
- High Debt LevelsEli Lilly has a high debt-to-equity ratio of 1.60 and a low free cash flow yield of 0.74%, raising financial concerns.
Watch whether new negative commentary on LLY points to these structural risks or is simply reacting to short-term price moves.
LLY Earnings Reaction — What the Last Quarter Showed
Last Quarter
- EPS
- $8.55 vs $6.97 est.Beat 22.7%
- Revenue
- $19.8B vs $17.8B est.Beat 11.1%
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into LLY consensus models and risk factors.
View Analysis
Should I Buy LLY?
Wall Street verdict, signals, and target summaries.
See Verdict
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
LLY — Frequently Asked Questions
Quick answers to the most common questions about buying LLY stock.
Should I buy LLY stock right now?
Verdict
LLY has modest upside — analysts rate it "Buy" with a $1271 target, implying +15.8% from today's $1098.13. This is informational only — verify the data and consider your own risk tolerance before deciding.
Is now a good time to buy LLY?
Timing
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +15.8% upside to the $1271 target. In the past 30 days, 2 of 2 covering analysts raised their price targets — a bullish signal.
What is the price target for LLY stock?
Price Target
LLY's consensus 12-month price target is $1271, set by 45 Wall Street analysts. The bull case high is $1400 and the bear case low is $1119. From the current price of $1098.13, this implies +15.8% upside.
Is LLY overvalued or undervalued?
Valuation
LLY appears undervalued — the $1271 consensus target is +15.8% above today's $1098.13. It trades at a forward P/E of 30.0x. Targets range from $1119 (bear) to $1400 (bull), reflecting different assumptions about growth and margins.
Should I buy LLY before earnings?
Earnings
LLY reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $1271 target. Consider position sizing rather than going all-in pre-print.
What are analysts saying about LLY stock?
Coverage
Of 45 analysts covering Eli Lilly and Company (LLY): 0 Strong Buy, 33 Buy, 9 Hold, 3 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $1271 (range $1119–$1400). Bullish analysts outnumber bearish by more than 2-to-1.
What are the risks of buying LLY stock?
Risks
3 of the 45 analysts covering LLY rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Eli Lilly and Company.
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.